ClinicalTrials.gg
CompletedNCT00322231Updated Jan 26, 2015Results posted

A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)

A Phase 3 interventional study of zoster vaccine live (ZOSTAVAX™) and Comparator: Placebo in Herpes Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
17th of 29
101 · median 160
Started
2006
the only one that year
Phase 3
9 of 29
none open now
Registered
3rd of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 17th largest by enrollment, is the only one that started in 2006, is one of 9 in phase 3, and was the 3rd registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to participants with a history of herpes zoster.

03

Conditions studied

  • Herpes Zoster

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 50 years of age with a history of herpes zoster ≥ 5 years prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • History of allergy to any vaccine component
  • Prior receipt of a varicella or zoster vaccine
  • Ability to defend against infection is suppressed by a medical condition or medication
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    ZOSTAVAX™ / Placebo

    Zoster vaccine live on Day 1 (Period 1), placebo on Week 4 (Period 2)

    Biological: zoster vaccine live (ZOSTAVAX™) · Biological: Comparator: Placebo

  • Experimental
    Placebo / ZOSTAVAX™

    Placebo on Day 1 (Period 1), zoster vaccine live on Week 4 (Period 2)

    Biological: zoster vaccine live (ZOSTAVAX™) · Biological: Comparator: Placebo

Interventions

  • 1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live

    Also known as: Zostavax

  • BiologicalComparator: Placebo

    1 dose 0.65 mL/dose subcutaneous injection of placebo.

06

What researchers measure

Primary outcomes

  1. Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination

    SAEs are AEs at any dose that: Results in death or persistent/significant disability/incapacity; or prolongs an existing inpatient hospitalization or Is life threatening; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose or Is an other important medical event

    Time frame: To Day 28 postvaccination

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination

    The GMT of the VZV-specific antibody responses as measured by gpELISA (glycoprotein enzyme-linked immunosorbent assay) at the prespecified day ranges at prevaccination and 4 weeks postvaccination

    Time frame: 4 weeks postvaccination

  2. Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination

    GMFR of the VZV antibody response at the prespecified day ranges prevaccination and 4 weeks postvaccination

    Time frame: From prevaccination (baseline) to 4 weeks postvaccination

07

Results

Posted Dec 15, 2010

Participant flow

Patients were recruited at 9 sites in the United States. First patient enrolled: May-2006; Last patient last visit: July - 2007

Period 1
Participant flow — Period 1
MilestoneZOSTAVAX™ / PlaceboPlacebo / ZOSTAVAX™
Started5150
Completed5150
Not completed00
Period 2
Participant flow — Period 2
MilestoneZOSTAVAX™ / PlaceboPlacebo / ZOSTAVAX™
Started5149
Completed5149
Not completed00

Outcome measures

PrimaryVaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination

SAEs are AEs at any dose that: Results in death or persistent/significant disability/incapacity; or prolongs an existing inpatient hospitalization or Is life threatening; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose or Is an other important medical event

Time frame:
To Day 28 postvaccination
Reported as:
Number · Participants
Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination
ParticipantsZOSTAVAX™Placebo
With Vaccine-related SAEs00
Without Vaccine-related SAEs100101
SecondaryGeometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination

The GMT of the VZV-specific antibody responses as measured by gpELISA (glycoprotein enzyme-linked immunosorbent assay) at the prespecified day ranges at prevaccination and 4 weeks postvaccination

Time frame:
4 weeks postvaccination
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination
gpELISA units/mLZOSTAVAX™Placebo
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination810.1 (688.3 to 953.4)391.1 (291.9 to 523.9)
SecondaryGeometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination

GMFR of the VZV antibody response at the prespecified day ranges prevaccination and 4 weeks postvaccination

Time frame:
From prevaccination (baseline) to 4 weeks postvaccination
Reported as:
Number · Geometric mean fold rise
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination
Geometric mean fold riseZOSTAVAX™Placebo
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination2.1 (1.8 to 2.4)1.0 (0.9 to 1.1)

Adverse events

Collected over Day 1 - 28 following each vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZOSTAVAX™—0/98 (0%)45/98 (45.9%)
Placebo—0/96 (0%)4/96 (4.2%)
Most frequent other events
Most frequent other events
EventZOSTAVAX™Placebo
Injection Site PainGeneral disorders36/981/96
Injection Site ErythemaGeneral disorders33/983/96
Injection Site SwellingGeneral disorders26/982/96
Injection Site PruritusGeneral disorders5/980/96

Baseline characteristics

Age, Customized
Age, Customized(participants)ZOSTAVAX™ / PlaceboPlacebo / ZOSTAVAX™Total
50 to 59 Years of age101020
≥ 60 Years of age414081
Sex: Female, Male
Sex: Female, Male(Participants)ZOSTAVAX™ / PlaceboPlacebo / ZOSTAVAX™Total
Female362460
Male152641
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ZOSTAVAX™ / PlaceboPlacebo / ZOSTAVAX™Total
Asian134
Black336
Hispanic American022
White474289
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Mills R, Tyring SK, Levin MJ, Parrino J, Li X, Coll KE, Stek JE, Schlienger K, Chan IS, Silber JL. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010 Jun 7;28(25):4204-9. doi: 10.1016/j.vaccine.2010.04.003. Epub 2010 Apr 21. PubMed 20416263 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2006
First posted
May 5, 2006
Start
May 2006
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Results first posted
Dec 15, 2010
Last update
Jan 26, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00322231
Responsible party
Sponsor
First posted
May 5, 2006
Start date
May 2006
Primary completion
Jul 2007
Completion
Jul 2007
Results posted
Dec 15, 2010
Last update
Jan 26, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion